Coronavirus: Are you approaching the vaccine? | Canberra Times

Coronavirus,

Once it looked like we were in Australia, dodging bullets. While the virus is widespread in other countries, we probably think our heroic efforts are being rewarded by a quick return to a successful normalization. However, the full outbreak in Victoria and the expanding Spotfire in Sydney reinforces the belief that only vaccines will really stop this. So what is the state of play? There is. Over the past week or so, several groups of researchers have reported that their trials on real people have been successful. Oxford University and the pharmaceutical company AstraZeneca have published promising results from the first two phases of the joint trial. Researchers tested the compound in 1,077 healthy adults between the ages of 18 and 55 and found that “a single dose of AZD1222 (a candidate vaccine) increased antibody four-fold”. It was Separately, American company Moderna said the test also turned out to be positive. Vaccines developed by Cansino Biologics in China, Pfizer Pharmaceuticals in the US, and BioNTech in Germany have also shown promising signs. Not so early. The World Health Organization says there are 140 groups worldwide studying vaccines, four of which are in a very important Phase 3 trial. Vaccines are computer-developed, developed in laboratory test tubes and petri dishes, and then moved closer to the human body. Scientists theorize what is successful with the disease and does not cause harmful side effects. When all that theory is added together, there is a stage of trial. Phase 1 targets a small group of adults, typically 80 or less. It assesses the safety of vaccines and provides information on how the vaccine works in the recipient’s body. Phase 2 involves a larger group of people, some of whom are at risk of contracting the disease. The goal is to study safety, including side effects, but primarily to see if a potential vaccine will prevent people from getting sick and then immunize. Phase 3 is big. It’s a large-scale test of whether the vaccine really works. Dose is given to people in areas where the disease is endemic. Results from different groups are compared. Many people are involved in this phase. For example, Oxford’s study tests the substance on people in Brazil and South Africa where COVID-19 is prevalent. It is currently in Phase 3 with four studies. Even if Phase 3 is successful, vaccines still need regulatory approval. Production should ideally be set up on a large scale to vaccinate the Earth’s population. If you think you need to rush any of these, consider thalidomide. Thalidomide is intended to help pregnant women with morning sickness and has also caused problems for babies. There are signs that the government is taking my first place. Last week, the Trump administration announced a $2.8 billion contract between Pfizer and a German biotechnology company for 100 million vaccine doses if the vaccine were successful. The UK government has signed 190 million potential vaccine contracts from two groups. At the end of June, the US government announced that it had secured a full supply of drugs (helping, not therapeutic vaccines) that could shorten hospital stays for COVID-19 patients. Who knows who else is trying to hunt down the market? There are no announcements that Australian authorities are making sure vaccine buyers go tens of millions of times in this direction. Joel Lexin, professor of Canadian health policy, said: “I don’t think we’re all together. It looks like a world of dog food. The groups most likely to eat are those living in low and middle income countries.” But another There is a view of. The group called COVAX consists of WHO, the Bill and Melinda Gates Foundation, research groups and pharmaceutical companies in more than 150 countries. According to the World Health Organization, its aim is to “guarantee fast, equitable and equitable access to the COVID-19 vaccine for the rich and poor in all countries of the world.” The countries involved make up 60% of the world’s population, but have not been identified. It is unknown if Australia is a member. It goes without saying that there are some questions to solve. “Under the agreement, rich countries will get the first crack with enough vaccines to cover 20 percent of their population, and only then will poor countries be vaccinated-and their highest priority. “For high ranking people only,” says Professor Lectin. If a vaccine occurs and production cannot meet the demand, how should it be distributed? Should healthcare professionals be the first? How about the elderly? How about a very old person? Who has the money to buy it? The Philosophy Department may be tackling these life and death conundrums, but politicians have said nothing. It is under the heading “Cross the bridge”. Professor Adrian Esterman, an epidemiologist at the University of South Australia, said in the paper that he was more optimistic than two months ago. He believes the Oxford University results are particularly promising. They show that their candidate vaccine may show more in boosters that they may immunize for at least 56 days. One question that hasn’t been answered yet is whether it will work for older people and young people. Read more: If everything goes as planned, he believes that by the end of the year there will be a vaccine and production will begin early in the next year. However, it is not 100% certain.

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/pMXRnDj3SUU44AkPpn97sC/b54a6f26-1d9e-4164-8f93-1d178f4db2e8.jpg/r757_134_3783_1844_w1200_h678_fmax.jpg